Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus

被引:10
作者
Bidoli, P [1 ]
Stani, SC [1 ]
De Candis, D [1 ]
Cortinovis, D [1 ]
Parra, HS [1 ]
Bajetta, E [1 ]
机构
[1] Ist Nazl Tumori, Med Oncol Unit B, I-20133 Milan, Italy
来源
TUMORI JOURNAL | 2001年 / 87卷 / 05期
关键词
esophagus; squamous cell carcinoma; vinorelbine;
D O I
10.1177/030089160108700504
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: At least half of the patients with squamous cell carcinoma of the esophagus (SCCE) present at diagnosis with metastatic disease, and most patients in a locally advanced phase will develop metastases despite potentially curative local therapy. Thus, the majority of patients with SCCE will become candidate for palliative chemotherapy. Only a few drugs have demonstrated moderate activity (> 15%) against SCCE. The main purpose of this phase II trial was to assess the activity of vinorelbine, a semisynthetic vinca alkaloid with a wide spectrum of action, in advanced or relapsed SCCE. Methods: Seventeen patients were included in the trial. Eleven of them had already received chemotherapy (cisplatin and fluorouracil) and/or radiotherapy at the time of the first diagnosis. All patients were treated with vinorelbine at the dose of 30 mg/m(2) every two weeks. Results: Sixteen of the 17 patients enrolled in the trial were assessable for activity: partial responses were observed in 4 of the 16 (25%), and 3 of them were pre-treated patients. A significant improvement of dysphagia was obtained in 4 of 11 symptomatic patients. Toxicity was mild, with only one episode of grade 4 neutropenia and constipation. Conclusions: In our experience, single-agent vinorelbine is active against SCCE. It was also active in patients previously treated with cisplatin and fluorouracil. The good tolerability and the possibility of relieving symptoms such as dysphagia strongly suggest the addition of vinorelbine to combination regimens with cisplatin as front-line chemotherapy for SCCE.
引用
收藏
页码:299 / 302
页数:4
相关论文
共 11 条
[1]   Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus [J].
Ajani, JA .
CHEST, 1998, 113 (01) :112S-119S
[2]   ACTIVITY OF TAXOL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS [J].
AJANI, JA ;
ILSON, DH ;
DAUGHERTY, K ;
PAZDUR, R ;
LYNCH, PM ;
KELSEN, DP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (14) :1086-1091
[3]  
BIDOLI P, 1994, FORUM TRENDS EXP CLI, V4, P638
[4]   Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma [J].
Conroy, T ;
Etienne, PL ;
Adenis, A ;
Wagener, DJT ;
Paillot, B ;
Francois, E ;
Bedenne, L ;
Jacob, JH ;
Seitz, JF ;
Bleiberg, H ;
VanPottelsberghe, C ;
VanGlabbeke, M ;
Delgado, FM ;
Merle, S ;
Wils, J .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :164-170
[5]  
Enzinger PC, 1999, SEMIN ONCOL, V26, P12
[6]   Vinorelbine: An overview [J].
Johnson, SA ;
Harper, P ;
Hortobagyi, GN ;
Pouillart, P .
CANCER TREATMENT REVIEWS, 1996, 22 (02) :127-142
[7]  
KELSEN DP, 1979, CANCER TREAT REP, V63, P2019
[8]   SURGICAL THERAPY OF ESOPHAGEAL-CARCINOMA [J].
MULLER, JM ;
ERASMI, H ;
STELZNER, M ;
ZIEREN, U ;
PICHLMAIER, H .
BRITISH JOURNAL OF SURGERY, 1990, 77 (08) :845-857
[9]  
Reed C E, 1999, Oncologist, V4, P95
[10]  
WHO, 1979, WHO HDB REP RES CANC, P48